A Havelock North woman, Julie Haines, has petitioned the New Zealand government to mandate breast density reporting and fund supplementary screening after a breast cancer diagnosis surfaced just three weeks after a clear mammogram.
The petition, supported by Breast Cancer Foundation NZ, seeks to address the diagnostic limitations of dense tissue.
The core of the issue lies in the masking effect of dense breast tissue, which can obscure tumors during standard mammographic screenings. Julie Haines, 51, was diagnosed with breast cancer in December 2024 despite having no family history of the disease and a clear mammogram performed only weeks earlier.
“Even though I'd been told by a specialist that I had dense breasts, I didn't understand what that meant because it's not really public knowledge in New Zealand,” Julie Haines told New Zealand Doctor
Tissue Masking Reduces Detection
- The Masking Effect: Dense tissue appears white on a mammogram, and since breast tumors also appear white, the tissue can “mask” the presence of cancer, making it difficult for radiologists to identify abnormalities.
- Risk Correlation: Women with high breast density have a statistically higher risk of developing breast cancer compared to those with lower density.
- Supplementary Screening: For women with dense tissue, supplementary imaging like ultrasound or contrast-enhanced mammography may increase the probability of early detection by providing a different contrast mechanism to differentiate between healthy and malignant tissue.
Petitioning for Regulatory Changes in BreastScreen Aotearoa
The petition, which closes on December 20, calls for BreastScreen Aotearoa to change how it communicates results. Haines began advocating for this change in May 2025, when she first contacted her local MP, Catherine Wedd. Her efforts gained momentum after she observed media coverage in September 2026 regarding another patient whose cancer was identified at a significantly advanced stage due to similar diagnostic challenges.
Breast Cancer Foundation NZ chief executive Vanessa Sorenson argues that the current system places an unfair financial burden on patients. "Julie did everything available to her, but she had to pay for the test that found her cancer. A woman’s chance of early detection shouldn’t be based on her ability to pay," Sorenson told New Zealand Doctor.
Mammography Sensitivity Decreases
The diagnostic challenge described by Haines is a well-documented phenomenon in oncological imaging. Standard digital mammography relies on X-ray attenuation, where denser structures absorb more radiation. While highly effective as a population-level screening tool, its sensitivity decreases in the presence of fibroglandular tissue, which has similar attenuation properties to potential lesions.
| Imaging Modality | Primary Mechanism | Utility in Dense Tissue |
|---|---|---|
| Digital Mammography | X-ray attenuation | Reduced sensitivity; potential masking |
| Breast Ultrasound | High-frequency sound waves | Improved detection of masses in dense tissue |
| Contrast-Enhanced Mammography | Vascular uptake of contrast | High sensitivity; identifies active tumor blood flow |
The urgency of the petition stems from the clinical reality that early detection remains the primary driver of improved prognosis. Following her diagnosis in December 2024, Haines underwent a lumpectomy in January 2025, followed by radiation. Because her cancer was identified via a self-funded ultrasound—after the initial mammogram was clear—she avoided more invasive treatments such as a mastectomy or systemic chemotherapy.
“I went into the ultrasound fully expecting it to be normal. When the technician started drawing on my breast and asked someone else to look at the screen, I knew something wasn't right,” Julie Haines said.
Consult a Doctor with Dense Tissue
While mammography remains the gold standard for population-wide screening, it is not a diagnostic tool for everyone in every circumstance. Patients who have been previously informed of dense breast tissue should consult their primary care provider or a radiologist to discuss their specific risk profile.
If a patient experiences new symptoms—such as a palpable lump, skin changes, or nipple discharge—they should seek a clinical examination regardless of the date of their last routine screening. Those with a high-risk family history or known genetic predispositions (such as BRCA1 or BRCA2 mutations) may require more frequent or specialized screening protocols beyond the standard biennial program.
The Ministry of Health has yet to announce a formal change to the current screening policy, citing that the issue remains under consideration. As the petition deadline of December 20 approaches, the focus remains on whether the next government will prioritize the disclosure of breast density as an essential component of informed patient consent.